Serum concentrations of interleukin-2 soluble receptor (IL-2 sR) in patients with vitiligo: Relationship with type and extent of the disease

Acta Dermatovenerologica Croatica

Volumn 12, Issue 2, 2004, Pages 71-76

  Franczuk, Anna ^a   Szepietowski, Jacek C ^a   Noworolska, Anna ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Adult; Child; Pigmentation disorders; Receptors, interleukin 2; Vitiligo

Indexed keywords

INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 SOLUBLE RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SERUM; SKIN PIGMENTATION; VITILIGO;

ADULT; AGED; CASE-CONTROL STUDIES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; VITILIGO;

EID: 2942744555     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. nd ed. Berlin: Springer Verlag; 2000. p. 1033-7.
2. Jimbow K. Vitiligo. Therapeutic advances. Dermatol Clin 1998;16:399-407.
3. Itoh M, Goto Y, Ohta Y, Ohashi H. Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Rheumatol 1998;17:26-30.
4. Kono N, Kanda Y, Yamamoto R, Chizuka A, Suguro M, Hamaki T, et al. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan. Leuk Lymphoma 2000;37:151-6.
5. Lee Y, Shin K, Lee E. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor and von Willebrand factor in systemic sclerosis. Clin Exp Rheumatol 2001;19:69-74.
6. Spadaro A, Riccieri V, Benfari G, Scillone M, Taccari E. Soluble interleukin-2 receptor in Sjogren's syndrome: relation to main serum immunological and immunohistochemical parameters. Clin Rheumatol 2001;20:319-23.
7. Tishler M, Yaron I, Shirazi I. Salivary and serum soluble interleukin-2 receptor in primary Sjogren's syndrome. Arch Oral Biol 1999;44:305-8.
8. Matsumoto T, Furukawa A, Sumiyoshi Y. Serum levels of interleukin-2 receptor in renal cell carcinoma. Urology 1998;51:145-9.
9. Nakata B, Chung K, Kato Y, Yamachita Y, Inui A, Arimoto Y, et al. Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer. Br J Cancer 1998;77:1820-4.
10. Suenaga Y, Yasuda M, Yamamoto M, Nonaka S, Wada T, Shiokawa S, et al. Serum interleukin-2 receptor for the early diagnosis of rheumatoid arthritis. Clin Rheumatol 1998;17:311-7.
11. Tsukamoto S, Ishikawa S, Yamauchi A, Saitou S. Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery. Hinyokika Kiyo 2000;46:695-9.
12. Bilińska M, Frydecka I, Podemski R. Clinical course and change of soluble interleukin-2 receptor and soluble forms of intercellular adhesion molecule-1 (ICAM-1) in serum of multiple sclerosis patients [in Polish]. Neurol Neurochir Pol 2001;35:47-56.
13. Bilińska M, Frydecka I, Podemski R. The level of soluble forms of interleukin-2 receptor and adhesive molecules ICAM-1 and VCAM-1 in platelets of multiple sclerosis patients [in Polish]. Pol Merkuriusz Lek 1999;6: 23-6.
14. Betti R, Rosti A, Bencini PL, Paparelli S, Gazzola GB, Cori P, et al. Effects of UVB plus tar therapy on serum levels of interleukin-2 receptors in patients with psoriasis. Int J Dermatol 1991;16:364-6.
15. De Rie MA, Zonneveld IM, Witkamp L, Van Lier RA, Out TA, Bos JD. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol 1996;76:357-60.
16. Kemmett D, Symons J, Colver G, Duff GW. Serum soluble interleukin 2 receptor in psoriasis: failure to reflect clinical improvement. Acta Derm Venereol 1990;70:264-7.
17. Kagi M, Joller J, Wuithrich B. Correlation of eosinophils, cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology 1992;185:88-92.
18. Kapp A, Piskorski A, Schopt E. Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol 1988;119:707-10.
19. Vonderheid EC, Zhang Q, Lessin SR, Polansky M, Abrams RD, Wasik MA. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998;38:207-20.
20. Mosteller R. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098.
21. Cui J, Arita Y, Eisinger N. Chatacterization of vitiligo antigens. J Invest Dermatol 1992;98:600-5.
22. Cui J, Harning R, Henn M, Bystryn JC. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992;98:162-5.
23. Naughton G, Eisinger M, Bystryn J. Antibodies to normal human melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983;81:540-2.
24. Park YM, Kim NS, Hann SK, Im S. Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients. J Dermatol Sci 1996;11:111-20.
25. Yu J, Kao C, Yu C. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with nonsegmental-type vitiligo. J Invest Dermatol 1993;100:823-8.
26. van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das P. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000;80:1299-309.
27. Wolkentein P, Revuz J, Guillaume JC, Avril MF, Chosidow O. Autoimmune disorders and interleukin-2 therapy: a step toward unanswered questions. Arch Dermatol 1995;131:615-21.
28. Honda Y, Okubo Y, Koga M. Relationship between levels of soluble interleukin-2 receptors and the types and activity of vitiligo. J Dermatol 1997;24:561-3.
29. Yeo UC, Yang YS, Park KB, Sung HT, Jung SY, Lee ES, et al. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J Dermatol Sci 1999;19:182-8.
30. Caixia T, Hongwen F, Xiran L. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci 1999;21:59-62.
31. Gotoh Y, Okamoto Y, Uemura O, Mori N, Tanaka S, Ando T, et al. Determination of age-related changes in human soluble interleukin 2 receptor in body fluids of normal subjects as control value against disease states. Clin Chim Acta 1999;289:89-97.
32. Zola H, Ridings J, Elliott S, Nobbs S, Weedon H, Wheatland L, et al. Interleukin 2 receptor regulation and IL-2 function in the human infant. Hum Immunol 1998;10:615-24.
33. Mozzanica N, Frigerio U, Finzi AF, Cattaneo A, Negri M, Scaglione F, et al. T cell subpopulations in vitiligo: a chronobiologic study. J Am Acad Dermatol 1990;22:223-30.
34. Gunduz K, Ozturk G, Terzioglu E, Sebik F. T cell subpopulations and sIL-2R in vitiligo. J Eur Acad Dermatol Venereol 2002;16 Suppl 1:275.